GlassScriptPhysician profile
Ilya Gelman
NPI 1811008022
$30,044.31
in general payments reported to CMS, 2019-2025
68 companies · $3,406 in 2025
The $3,406 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,494 · 2021: $3,942 · 2022: $2,737 · 2023: $2,768 · 2024: $2,493 · 2025: $3,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,629 · Education: $37.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,629.42 |
| Education | $37.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $12,332.65 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $1,743.32 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $1,710.61 | 2019-2025 | |
| Amarin Pharma, INC. | $1,073.91 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $937.57 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Novartis Pharmaceuticals Corporation | $879.49 | 2019-2025 | |
| Ibsa Pharma INC. | $782.13 | 2020-2025 | Tirosint, Licart, Tirosint |
| Glaxosmithkline, LLC. | $762.17 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $706.62 | 2021-2025 | |
| Edwards Lifesciences Corporation | $686.56 | 2019-2025 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $647.21 | 2019-2025 | Taltz, Mounjaro, Zepbound |
| Allergan, INC. | $535.41 | 2019-2022 | |
| Novo Nordisk INC | $523.92 | 2019-2025 | Wegovy, Ozempic |
| Radius Health, INC. | $500.69 | 2021-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $463.75 | 2019-2024 | Xarelto |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Gelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.